SCHEMBL12698149

SCHEMBL12698149

CCOC(=O)c1nn(C)c2c1CCC/C(=C\N(C)C)C2=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 5/20 0.40
CDK2 P24941 5/20 0.40
CCNA1 P78396 4/20 0.40
CDK4 P11802 2/20 0.40
CCND3 P30281 2/20 0.40
CDK6 Q00534 1/20 0.40
ALDH1A1 P00352 8/20 0.40
KDM4E B2RXH2 6/20 0.40
HPGD P15428 3/20 0.40
TP53 P04637 3/20 0.40
POLB P06746 4/20 0.37
HSD17B10 Q99714 3/20 0.37
ESR1 P03372 1/20 0.37
TSHR P16473 1/20 0.37
NR4A1 P22736 1/20 0.37
MAPT P10636 4/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
BRD4 O60885 1/20 0.34
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1558480 0.94 CCNA2 (0.44) CCNA2CDK2CCNA1CDK4CCND3
SCHEMBL1558479 0.94 CCNA2 (0.44) CCNA2CDK2CCNA1CDK4CCND3
SCHEMBL10216353 0.94 CCNA2 (0.44) CCNA2CDK2CCNA1CDK4CCND3
SCHEMBL25626842 0.84 ALDH1A1 (0.40) CCNA2CDK2CCNA1CDK4CCND3
SCHEMBL12499446 0.83 CCNA2 (0.35) CCNA2CDK2CCNA1POLBMAPT
SCHEMBL12499450 0.83 CCNA2 (0.35) CCNA2CDK2CCNA1POLBMAPT
SCHEMBL6053032 0.83 CCNA2 (0.43) CCNA2CDK2CCNA1CDK4CCND3
SCHEMBL3503706 0.83 ALDH1A1 (0.42) CCNA2CDK2CCNA1CDK4CCND3
SCHEMBL3503708 0.83 ALDH1A1 (0.42) CCNA2CDK2CCNA1CDK4CCND3
SCHEMBL3502598 0.83 ALDH1A1 (0.41) CCNA2CDK2CCNA1CDK4CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668188-B1 TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-05-18 EP disclosed
US-8916577-B2 Tricyclic derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-12-23 US disclosed
US-8916577-B2 Tricyclic derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-12-23 US disclosed
US-20130302416-A1 TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-11-14 US disclosed
US-20130302416-A1 TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-11-14 US disclosed
WO-2012101029-A1 TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302416-A1 TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS CDK1, MAP3K1, MAP3K20 CCNA2 239/4885CDK2 16/4885CCNA1 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.